NICE on the offensive in row over breast cancer drug

Hand with pills

NICE has taken the unprecedented step of expressing its ‘disappointment’ with a multinational drug giant in a row over a new breast cancer drug and the government’s pricing deal

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here